Review article · 2026 · Open access
Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains
Drug Discovery Today, 31(6), 104843 · Published 27 October 2026 · DOI 10.1016/j.drudis.2026.104843
In brief
“Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains” is a 2026 review article by Yohan Seo and Joohan Woo, published in Drug Discovery Today. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Drug Discovery Today.
- Citations
- 0
- References
- 97
- Authors
- 2
Abstract
Receptor-directed therapeutics now dominate type 2 diabetes, yet their clinical value depends on more than target biology. This review proposes a pharmaceutics-centered framework spanning the receptors for glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon, amylin co-agonism and selected nutrient-sensing receptors, it then tests against a defined cohort of 49 programs that reached Phase II in type 2 diabetes. Among arrests with a disclosed scientific cause, modality predominates; two-thirds of arrests were unexplained or attributed to portfolio decisions. Deliverability discriminates among comparable mechanisms, cannot raise a low receptor ceiling and is poorly served by the public record.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Seo, Y., & Woo, J. (2026). Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains. Drug Discovery Today, 31(6), 104843. https://doi.org/10.1016/j.drudis.2026.104843
MLA 9
Seo, Yohan, and Joohan Woo. “Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains.” Drug Discovery Today, vol. 31, no. 6, 2026, p. 104843. https://doi.org/10.1016/j.drudis.2026.104843.
Chicago
Seo, Yohan and Joohan Woo. 2026. “Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains.” Drug Discovery Today 31 (6): 104843. https://doi.org/10.1016/j.drudis.2026.104843.
Harvard
Seo, Y. and Woo, J. (2026) ‘Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains’, Drug Discovery Today, 31(6), p. 104843. doi:10.1016/j.drudis.2026.104843.
IEEE
Y. Seo and J. Woo, “Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains,” Drug Discovery Today, vol. 31, no. 6, p. 104843, 2026, doi: 10.1016/j.drudis.2026.104843.
BibTeX
@article{seo2026incretin,
title = {{Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains}},
author = {Seo, Yohan and Woo, Joohan},
journal = {Drug Discovery Today},
year = {2026},
volume = {31},
number = {6},
pages = {104843},
doi = {10.1016/j.drudis.2026.104843},
url = {https://doi.org/10.1016/j.drudis.2026.104843}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- type 2 diabetes
- incretin receptor agonists
- G protein-coupled receptors
- GLP-1 receptor
- GIP receptor
- glucagon receptor
- drug development failure
- drug delivery
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Seo, Y., & Woo, J. (2026). Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains. Drug Discovery Today, 31(6), 104843. https://doi.org/10.1016/j.drudis.2026.104843
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Drug Discovery Today: sign in and open the PDF from this page.
Who wrote this paper?
Yohan Seo, Joohan Woo.
What is the DOI of this paper?
10.1016/j.drudis.2026.104843, permanently at https://doi.org/10.1016/j.drudis.2026.104843. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.